England Throw It Away: Scientific Defence Unworthy of a Top Nation

For decades, British science punched well above its weight. From the discovery of DNA’s structure to the development of monoclonal antibodies, the United Kingdom produced Nobel laureates and world-changing innovations at a rate that belied its modest population. Yet, as of 2026, that glorious innings is being squandered by a defensive strategy unworthy of a top nation. England—and by extension the UK—is throwing away its scientific advantage through a combination of underfunding, misdirected priorities and a regulatory environment that stifles the very entrepreneurship that once drove progress.

This is not a lament from the usual suspects. The data is unambiguous. According to the latest OECD Science, Technology and Innovation Outlook, the UK’s gross domestic expenditure on R&D (GERD) as a percentage of GDP has stagnated at around 1.7% for the past five years, well below the 3% target set by successive governments and trailing behind Germany (3.1%), the United States (3.5%) and even South Korea (4.6%). The private sector, which should be the engine of innovation under a liberal-conservative framework, is being choked by uncertainty. The post-Brexit settlement with Horizon Europe, while technically restored, has created a labyrinth of bureaucratic hurdles that small and medium-sized enterprises—the true job creators—cannot navigate. The result? A brain drain that is accelerating. The Royal Society’s 2025 report, “The State of UK Research”, noted that 42% of early-career researchers are considering leaving the country within the next three years, citing funding instability and a hostile visa regime for international talent.

But the rot goes deeper than money. The “defence” in the title is not merely military. It is the defensive posture of a scientific establishment that has become risk-averse, centralised and addicted to government grants rather than market signals. The UK’s Research Excellence Framework (REF), meant to measure quality, has instead incentivised safe, incremental work over bold, disruptive ideas. Meanwhile, the state’s role in funding basic research has become a piggy bank for university administrators rather than a catalyst for commercial application. A liberal-conservative approach would argue for a leaner state: targeted tax credits for R&D, removal of planning restrictions that delay lab construction, and a radical simplification of the patent system for smaller entities. Instead, Whitehall has opted for more committees, more “strategic priorities” set by civil servants, and more layers of compliance that favour incumbents over upstarts.

The consequences are visible across every metric that matters. The UK’s share of global scientific publications has fallen from 7.6% in 2015 to 5.9% in 2025, according to the Nature Index. Its share of patents filed under the Patent Cooperation Treaty has dropped even more sharply, from 3.8% to 2.5% over the same period. In fields critical to future prosperity—artificial intelligence, quantum computing, synthetic biology—British-born talent is increasingly being commercialised in the United States or Singapore. The “golden triangle” of Oxford, Cambridge and London still produces world-class basic research, but the translation into high-growth companies is faltering. The number of UK-headquartered biotech unicorns has halved since 2020, while Israel, a country with fewer than 10 million people, now produces more per capita.

One might argue that this is a cyclical downturn, or that the pandemic-era surge in funding created unrealistic expectations. But the pattern is structural. The UK’s defence of its scientific position has been reactive, not proactive. When the European Research Council grants became harder to access, the government launched a weak “Horizon Europe alternative” that was under-advertised and under-resourced. When inflation eroded the real value of UK Research and Innovation (UKRI) budgets, the response was to cut overheads rather than increase the core grant. And when the private sector begged for a more predictable immigration system for skilled scientists, the Home Office offered a points-based system that still treats a Nobel laureate from India the same as a tourist. This is not the behaviour of a nation that understands that science is the ultimate competitive advantage in a free-market world.

From a liberal-conservative standpoint, the solution is not more state intervention but smarter, lighter intervention. The state should fund basic research—the kind that has no immediate commercial application but expands the frontiers of knowledge—and then get out of the way. It should slash corporate tax rates for R&D-intensive firms, eliminate the apprenticeship levy that penalises small labs, and open the door to global talent without the current Kafkaesque bureaucracy. It should also end the practice of using science funding as a tool for regional redistribution, which has diluted excellence in the name of equity. The market, not Whitehall, should decide which technologies scale. The UK’s historical success came from a culture of curiosity, property rights and light-touch regulation—not from five-year plans drafted by the Department for Science, Innovation and Technology.

Some will object that this is a recipe for inequality or that it ignores the “public good” nature of science. But the evidence shows that countries which embrace market-led innovation—the United States, Switzerland, Israel—consistently outperform those that treat science as a branch of the welfare state. The UK is neither fish nor fowl: it taxes and regulates like a continental social democracy, but it lacks the industrial policy coherence of France or Germany. The result is the worst of both worlds: high costs, low agility and a defensive crouch that turns every funding round into a political negotiation.

The coming decade will be decisive. If the UK continues to “throw it away” with a defensive posture that prioritises process over outcomes, it will become a scientific middle power—respected but not feared. The window to reverse this is narrowing. The next government, whatever its colour, must have the courage to abandon the incrementalism that has brought us here. Free the scientists, free the market, and let the discoveries come. Otherwise, the only thing England will be defending is its past glory.

**Q: Is the UK’s scientific decline irreversible?** A: No, but it requires a fundamental shift in policy. Reversing the trend would take at least a decade of sustained, market-friendly reforms. The talent base is still strong, but it is leaking.

**Q: Does FORTIS NEWS believe the government should have no role in science?** A: Not at all. The state should fund basic research and provide a stable legal framework for intellectual property. But it should avoid micromanaging research agendas and should remove barriers to private investment.

**Q: What about climate science and net-zero research?** A: Those areas have received disproportionate funding relative to their economic return. A liberal-conservative approach would redirect resources to fields with higher commercial potential, such as advanced materials, energy storage and AI, and let the market decide which green technologies are viable.

**Q: Is Brexit solely to blame?** A: Brexit exacerbated the problem by disrupting collaboration networks and adding administrative costs, but the decline began before 2016. The core issue is a domestic policy mindset that favours central planning over competition.

**Q: How can individual scientists or entrepreneurs help?** A: By voting with their feet and their capital. Those who stay should lobby for deregulation and tax reform. The UK still offers a strong rule of law and English-language advantages—but those are eroding.